Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
PROCF Quote, Financials, Valuation and Earnings
Last price:
$0.1100
Seasonality move
:
-24.44%
Day range:
$0.1100 - $0.1100
52-week range:
$0.0011 - $1.4700
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.03x
P/B ratio:
1,220.19x
Volume:
--
Avg. volume:
67
1-year change:
-92.52%
Market cap:
$256M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Sofgen Pharma SA has 4445.46% upside to fair value with a price target of -- per share.
PROCF vs. S&P 500
-
Over the past 5 trading days, Sofgen Pharma SA has underperformed the S&P 500 by -3.14% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sofgen Pharma SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sofgen Pharma SA has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Sofgen Pharma SA reported revenues of --.
Earnings Growth
-
Sofgen Pharma SA earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Sofgen Pharma SA reported earnings per share of --.
Enterprise value:
537M
EV / Invested capital:
--
Price / LTM sales:
0.03x
EV / EBIT:
12.03x
EV / Revenue:
1.27x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
13.42x
Price / Operating cash flow:
0.29x
Enterprise value / EBITDA:
8.55x
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Income Statement | ||||||
| Revenue | $409.7M | $409.9M | $423.7M | $101.5M | $111.1M | |
| Gross Profit | $235.7M | $192.4M | $238M | $52.3M | $62.3M | |
| Operating Income | $70.5M | -- | $44.6M | $2.2M | $13.1M | |
| EBITDA | $90M | -- | $62.8M | $6.7M | $18.3M | |
| Diluted EPS | -$2.27 | $0.25 | $0.40 | $0.09 | -$0.01 | |
| Period Ending | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.6M | $721.2K | $298.1M | $279.3M | $275.6M | |
| Total Assets | $202.1M | $202.1M | $462.1M | $442.5M | $472.5M | |
| Current Liabilities | $60.8K | $32K | $188M | $386.3M | $401.7M | |
| Total Liabilities | $60.8K | -- | $500.5M | $479.7M | $473.2M | |
| Total Equity | $202.1M | $202M | -$38.3M | -$37.1M | -$736K | |
| Total Debt | -- | -- | $253.4M | $38.2M | $36.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $18M | -- | $72.8M | -$7.8M | $26.4M | |
| Cash From Investing | -$25.5M | -- | -$34.6M | -$11.8M | -$14.3M | |
| Cash From Financing | $89.9M | -- | -$63M | $28.8M | -$14.1M | |
| Free Cash Flow | -$8.4M | -- | $40M | -$18.8M | $14M | |
PROCF
Sector
Market Cap
$256M
$24.3M
Price % of 52-Week High
7.48%
46.97%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.86%
1-Year Price Total Return
-92.52%
-17.65%
Beta (5-Year)
62.272
0.513
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.2200
200-day SMA
Sell
Level
$0.5683
Bollinger Bands (100)
Sell
Level
-0.195 - 0.585
Chaikin Money Flow
Buy
Level
1.1K
20-day SMA
Buy
Level
$0.1002
Relative Strength Index (RSI14)
Buy
Level
50.2980
ADX Line
Sell
Level
12.9335
Williams %R
Buy
Level
-88.9878
50-day SMA
Buy
Level
$0.0620
MACD (12, 26)
Buy
Level
0.0345
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Sell
Level
-1.6K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sofgen Pharma SA is an international healthcare and pharmaceutical company. The firm is engaged in the developing of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It operates through the following segments: NextGel, Procaps Colombia, CAN, CASAND, and Diabetrics. The NextGel segment is involved in the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in USA, Brazil, and Colombia. The Procaps Colombia segment is focused on the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in Colombia. The CAN segment deals with the manufacturing and distribution of prescription and over-the-counter pharmaceutical products in Northern Central America: Salvador, Guatemala, Nicaragua, and Honduras. The CASAND segment offers pharmaceutical products in Southern Central America that include Panama and Costa Rica, and the North Andes District that include Ecuador, Peru, and Bolivia. The Diabetrics segment consists of the diabetes solutions and chronic disease management tool. The company was founded by Ruben Minski in 1977 and is headquartered in Luxembourg.
Stock Forecast FAQ
In the current month, PROCF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PROCF average analyst price target in the past 3 months is --.
-
Where Will Sofgen Pharma SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sofgen Pharma SA share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Sofgen Pharma SA?
Analysts are divided on their view about Sofgen Pharma SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sofgen Pharma SA is a Sell and believe this share price will drop from its current level to --.
-
What Is Sofgen Pharma SA's Price Target?
The price target for Sofgen Pharma SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PROCF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sofgen Pharma SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of PROCF?
You can purchase shares of Sofgen Pharma SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sofgen Pharma SA shares.
-
What Is The Sofgen Pharma SA Share Price Today?
Sofgen Pharma SA was last trading at $0.1100 per share. This represents the most recent stock quote for Sofgen Pharma SA. Yesterday, Sofgen Pharma SA closed at $0.1100 per share.
-
How To Buy Sofgen Pharma SA Stock Online?
In order to purchase Sofgen Pharma SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PROCF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PROCF
Sector
P/E ratio
--
21.48x
PEG ratio
0.00x
-0.01x
P/B ratio
1,220.19x
1.72x
Price / LTM sales
0.03x
1.44x
Growth Metrics
PROCF
Sector
Revenue growth
--
3.36%
Earnings growth
--
14.79%
Revenue (5-year growth)
--
6.26%
Earnings forecast
--
-$0.22
Profitability
PROCF
Sector
Profitability FY 2026
--
$2.4M
Return on invested capital
--
-33.32%
Return on assets
--
-29.45%
Return on equity
--
-40.29%
Earnings Date
Last Earnings Date
Jun
24
Next Earnings Date
Apr
2
Estimated Next Earnings Date
Jul
2
Balance Sheet
PROCF
Sector
Total cash
--
$25.7M
Short term investments
--
$22.7M
Total assets
--
$70.4M
Long term debt
--
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
72
RGC alert for Apr 2
Regencell Bioscience Holdings Ltd. [RGC] is up 32.32% over the past day.
Sell
27
RH alert for Apr 2
RH [RH] is down 19.29% over the past day.
Sell
43
AXTI alert for Apr 2
AXT, Inc. [AXTI] is down 17.29% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
